LAUSR

The goal of this study was to see how important it is to monitor Mycoplasma pneumoniae-specific antibody IgM, C-reactive protein, and procalcitonin levels in the blood of kids with Mycoplasma pneumoniae pneumonia as a reference for clinical diagnosis and treatment. The study group consisted of 96 children who had mycoplasma pneumonia in our hospital between May 2020 and May 2021, and the control group consisted of 96 healthy children who had a routine physical examination in our hospital at the same time. C-reactive protein and procalcitonin were measured and compared. The application value of single detection and combined detection of Mycoplasma pneumoniae-specific antibody IgM, C-reactive protein, and procalcitonin in the diagnosis of Mycoplasma pneumoniae pneumonia was evaluated based on clinical diagnosis results. The detection values of C-reactive protein and procalcitonin in the study group were higher than those in the recovery period and the control group, P < 0.05; the detection values of C-reactive protein and procalcitonin in the study group were higher than those in the control group, P < 0.05. The combination detection of Mycoplasma pneumoniae-specific antibody IgM, C-reactive protein, and procalcitonin had a greater diagnostic accuracy than single detection (P < 0.05). The sensitivity was higher than C-reactive protein and procalcitonin (P < 0.05); the specificity and positive predictive value were higher than Mycoplasma pneumoniae-specific antibody IgM (P < 0.05); and the negative predictive value was higher than procalcitonin (P < 0.05). The clinical value of combining the detection of Mycoplasma pneumoniae-specific antibody IgM, C-reactive protein, and procalcitonin in the diagnosis of Mycoplasma pneumoniae pneumonia in children is higher than that of single item detection, and it can provide a reliable clinical reference, as well as aid in evaluating the recovery effect of children, and it is worthy of application.